Editas Medicine Linkedin .hamburger .st0{fill:none;stroke:#FFFFFF;stroke-width:0.5;} Overview The Editas Mission Our Leadership ABOUT EDITAS MEDICINE Pioneering the Possible Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases. Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO. We are pioneering the possibilities of genomic medicines through gene editing. Jump down to learn more about our work and the people who make it possible: The Editas Medicine Mission Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases. What We’re Working On We’re using CRISPR, a powerful genome editing technology to develop new gene edited medicines. We are researching and developing both in vivo gene edited medicines, which edit genes inside the body, and ex vivo gene edited cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients. Gene editing has the potential to change outcomes within a broad range of diseases. Right now, we’re concentrating our efforts on three major therapeutic areas. Ocular diseases Leber Congenital Amaurosis 10 (LCA10), Usher syndrome 2A (USH2A), retinitis pigmentosa (RP4) Blood diseases Sickle cell disease (SCD), Beta-thalassemia Oncology Developing both autologous and allogeneic ex vivo gene edited cell medicines for the treatment of solid tumors and blood cancers Our Leadership Success at Editas Medicine is driven by our exceptional team. We have intentionally built our company for and around the passionate scientists and experienced professionals who make our work possible. Together, we’re translating groundbreaking science into transformative medicines. Executive Leadership James (Jim) C. Mullen, Chairman, President, and Chief Executive Officer Bruce E. Eaton, Ph.D., Executive Vice President and Chief Business Officer Harry Gill, Senior Vice President, Operations Chi Li, Ph.D., MBA, RAC Senior Vice President and Chief Regulatory Officer Lisa A. Michaels, M.D., Executive Vice President and Chief Medical Officer Michelle Robertson, Chief Financial Officer Mark S. Shearman, Ph.D. Executive Vice President and Chief Scientific Officer Charlene Stern, Ph.D., J.D., Senior Vice President and Chief Legal Officer Executive Leadership Board of Directors Our Scientific Founders Research and Pipeline CRISPR Gene Editing For Patients Who We Are Join Our Team Investors Terms of Use Privacy Policy Get in Touch Newsroom Editas Medicine Linkedin ©Copyright 2021 Editas Medicine